| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Function: Pirfenidone (PFD) is a novel kind of ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It into into market in Shionogi, Japan in 2008 and has been approved by the US drug and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has its effectiveness in treatment idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treatment some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. accident, it is also extensive applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, of neurofibromatosis and plexiform neurofibromas, diabetes union with kidney disease.
|
|||||||||||
|
Product name
|
CAS No.
|
|
β-Nicotinamide Mononucleotide (NMN)
|
1094-61-7
|
|
beta-Diphosphopyridine nucleotide (NAD)
|
53-84-9
|
|
Nicotinamide riboside chloride (NRC)
|
23111-00-4
|
|
Nicotinamide Ribose (NR)
|
1341-23-7
|
|
|
53-43
|
Extraction process:
){kind=link}